Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex for Reversal of Neuromuscular Blockade During Spinal Surgery
NCT04471376Completed
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jul 2020
- Primary completion
- Dec 2020
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of Sugammadex in neuromuscular blockade (NMB) (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Amplitude of Motor Evoked Potential. Started Jul 2020; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT04471376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04471376.